Feature

Abortion debate may affect Rx decisions for pregnant women


 

The upside of restrictions?

If there’s a positive side to these developments with abortion bans, it may encourage women taking new medications or joining clinical trials to think even more carefully about adherence to effective contraception, said Dr. Chambers.

Some methods are more effective than others, she emphasized. “When you have an unplanned pregnancy, it could mean that the method you used wasn’t optimal or you weren’t using it as recommended.” A goal moving forward is to encourage more thoughtful use of highly effective contraceptives, thus reducing the number of unplanned pregnancies, she added.

If patients are taking methotrexate, “the time to think about pregnancy is before getting pregnant so you can switch to a drug that’s compatible with pregnancy,” she said.

This whole thought process regarding pregnancy planning could work toward useful health goals, said Dr. Chambers. “Nobody thinks termination is the preferred method, but planning ahead should involve a discussion of what works best for the patient.”

Patients do have other choices, said Dr. Grifka. “Fortunately, there are many commonly prescribed medications which cross the placenta and have no ill effects on the fetus.”

Talking to patients about choices

Dr. Clowse, who spends a lot of time training rheumatologists, encourages them to have conversations with patients about pregnancy planning. It’s a lot to manage, getting the right drug to a female patient with chronic illness, especially in this current climate of abortion upheaval, she noted.

Her approach is to have an open and honest conversation with patients about their concerns and fears, what the realities are, and what the potential future options are for certain rheumatology drugs in the United States.

Some women who see what’s happening across the country may become so risk averse that they may choose to die rather than take a lifesaving drug that poses certain risks under new restrictions.

“I think that’s tragic,” said Dr. Clowse.

To help their patients, Dr. Gray believes physicians across specialties should better educate themselves about physiology in pregnancy and how to counsel patients on the impact of not taking medications in pregnancy.

In her view, it’s almost coercive to say to a patient, “You really need to have effective contraception if I’m going to give you this lifesaving or quality-of-life-improving medication.”

When confronting such scenarios, Dr. Gray doesn’t think physicians need to change how they counsel patients about contraception. “I don’t think we should be putting pressure on patients to consider other permanent methods just because there’s a lack of abortion options.”

Patients will eventually make those decisions for themselves, she said. “They’re going to want a more efficacious method because they’re worried about not having access to abortion if they get pregnant.”

Dr. Gray reports being a site principal investigator for a phase 3 trial for VeraCept IUD, funded by Sebela Pharmaceuticals. Dr. Clowse reports receiving research funding and doing consulting for GlaxoSmithKline.

*Correction, 6/2/2022: A previous version of this article misstated the intended use of drugs such as the “morning-after” pill (levonorgestrel). They are taken to prevent unintended pregnancy.

A version of this article first appeared on Medscape.com .

Pages

Recommended Reading

COVID-19 vaccination does not increase risk of flare in patients with lupus
Journal of Clinical Outcomes Management
FDA approves anifrolumab (Saphnelo) as first new lupus treatment in more than 10 years
Journal of Clinical Outcomes Management
Tocilizumab shortage continues as pandemic wears on
Journal of Clinical Outcomes Management
NIH to study COVID vaccine booster in people with autoimmune disease
Journal of Clinical Outcomes Management
Temporary hold of mycophenolate helps immune response to SARS-CoV-2 vaccination
Journal of Clinical Outcomes Management
FDA approves avacopan for rare ANCA autoimmune disease
Journal of Clinical Outcomes Management
mRNA COVID vaccine response found mostly robust in RA, SLE patients
Journal of Clinical Outcomes Management
FDA approves new myasthenia gravis drug
Journal of Clinical Outcomes Management
New ivermectin, HCQ scripts highest in GOP-dominated counties
Journal of Clinical Outcomes Management
COVID-19 infection linked to risk of cutaneous autoimmune and vascular diseases
Journal of Clinical Outcomes Management